Loading clinical trials...
Loading clinical trials...
The purpose of this study is to find out what effect the combination of fulvestrant (Faslodex) and dasatinib (Sprycel) has on advanced breast cancer compared to fulvestrant alone.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Bristol-Myers Squibb
NCT05831878 · Advanced Breast Cancer
NCT06997029 · Advanced Solid Tumor, Advanced Breast Cancer, and more
NCT07347600 · Locally Advanced Breast Cancer, Metastatic Breast Cancer
NCT07085767 · Breast Cancer, Locally Advanced Breast Cancer, and more
NCT06380751 · Advanced Breast Cancer
Northern Arizona Hematology & Oncology Associates
Sedona, Arizona
Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) Hope
Tucson, Arizona
Florida Cancer Institute - New Hope
Hudson, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions